Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program

Trial Profile

Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir/ritonavir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Zidovudine (Primary)
  • Indications HIV-2 infections
  • Focus Therapeutic Use
  • Acronyms RESIST-2
  • Most Recent Events

    • 25 Jan 2021 Biomarkers information updated
    • 20 Jan 2021 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped:COVID-19 and Funding.
    • 17 Jan 2020 Planned primary completion date changed from 1 Jan 2022 to 31 May 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top